Thermo Fisher earnings increased in the third quarter of 2026 as revenue rose 9% to $12.14 billion and operating margins widened. The scientific equipment and services company reported GAAP diluted earnings per share of $4.64, up 9%, and adjusted EPS of $6.68, up 15%, in its October 21 announcement covering the quarter ended September 26.
Key Takeaways
- Organic revenue grew 6%, compared with reported revenue growth of 9%.
- GAAP and adjusted operating margins each widened by 1.2 percentage points.
- Laboratory Products and Biopharma Services delivered the largest dollar increase in segment revenue.
Table of Contents
- Thermo Fisher earnings grow faster than revenue
- Segment growth was uneven
- Cash generation strengthens alongside product launches
- Full-year guidance was reserved for the earnings call
- Conclusion
Thermo Fisher earnings grow faster than revenue
The company’s third-quarter 2026 results announcement showed revenue increasing from $11.12 billion a year earlier. Acquisitions and divestitures contributed a net three percentage points to reported growth, while currency translation had no effect. Organic growth, a non-GAAP measure, excludes those effects.
GAAP operating income rose 17% to $2.26 billion, lifting the operating margin to 18.6% from 17.4%. Adjusted operating income increased 15% to $2.97 billion, with the corresponding margin rising to 24.5% from 23.3%. Both measures show operating profit growing faster than sales.
Net income attributable to Thermo Fisher reached $1.72 billion, compared with $1.62 billion a year earlier. A lower diluted share count also supported per-share earnings: weighted average diluted shares declined to 371 million from 378 million.
Adjusted EPS excludes items including acquisition-related intangible amortization and restructuring costs. It therefore differs from GAAP EPS and should be read alongside, rather than as a replacement for, the reported result.
| Item | Details |
|---|---|
| Life Sciences Solutions revenue | Q3 2026: $2.719 billion; Q3 2025: $2.588 billion. |
| Analytical Instruments revenue | Q3 2026: $2.002 billion; Q3 2025: $1.893 billion. |
| Specialty Diagnostics revenue | Q3 2026: $1.098 billion; Q3 2025: $1.174 billion. |
| Laboratory Products and Biopharma Services revenue | Q3 2026: $6.863 billion; Q3 2025: $5.970 billion. |
Segment growth was uneven
Laboratory Products and Biopharma Services accounted for the largest dollar increase in revenue among the four reporting segments. Life Sciences Solutions and Analytical Instruments also expanded, while Specialty Diagnostics revenue declined.
Profitability improved across all four segments despite that uneven sales performance. Analytical Instruments recorded the largest segment-margin increase, reaching 26.9% from 22.6%. Specialty Diagnostics increased its segment margin to 31.0% from 27.4%, even as revenue fell.
Cash generation strengthens alongside product launches
Operating cash flow increased to $2.55 billion from $2.24 billion in the prior-year quarter. Free cash flow, a non-GAAP measure, rose to $2.12 billion from $1.84 billion after capital spending and proceeds from property sales.
Thermo Fisher completed the previously announced sale of its microbiology business during the quarter. It also launched products spanning isotope-ratio analysis, electron microscopy, autoimmune testing and genomic sequencing.
The company and Mayo Clinic launched Precure, an initiative intended to combine data from more than one million patient samples with Thermo Fisher’s proteomics technologies. Separately, Thermo Fisher opened an AI-Automation Innovation Center in South Korea and a highly automated distribution center in Kentucky.
Full-year guidance was reserved for the earnings call
Chief Executive Officer Marc Casper attributed the quarter’s performance to the company’s growth strategy and PPI Business System. He said Thermo Fisher was well positioned to deliver an excellent 2026, but that statement was qualitative rather than a numerical forecast.
The release said updated 2026 financial guidance would be provided during the October 21 earnings call. The available call opening does not contain that update, so it does not establish a revised revenue or earnings range.
Conclusion
Thermo Fisher’s third quarter combined revenue growth with wider operating margins and stronger cash generation. The next item to verify is the numerical full-year guidance discussed on the October 21 call, which is not included in the available opening remarks.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
